fashion -WSS

fashion

author：leisure time 2025-09-30 22:28:01 - browse：2526

A product image of the Cue reader COVID-19 home use test — Businesswire via AP

The Food and Drug Administration warned consumers Monday to not use Cue Health’s at-home Covid-19 tests. This follows an FDA warning letter to the company last week that said Cue was not following the conditions stipulated in the emergency use authorizations for its tests.

The FDA letters said the tests could give false results. Specifically, the agency said that the company had changed how the electrochemical signals within the test device were generated, received, and interpreted — changes the FDA has not authorized. These changes decreased the stability of the tests and might lead to false results, the agency said.

The FDA warnings come near what might be the end of a spectacularly bumpy ride for the company. When Cue went public in 2021, it was valued at nearly $3 billion. It supplied tests for the NBA’s 2020 “bubble,” leading a Trump administration official to proclaim that if the test was “good enough for LeBron,” the administration would bring it to the American people — and it did, in a $481 million deal.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Pharma patents targeted by Biden in move to slash drug prices

focus

WSS

Food makers to regulators: Ultra

Generate Biomedicines machine learning biotech raises $273M

How medical schools plan to diversify without affirmative action

Americans' trust in science, scientist continues decline: Report

Walmart eyes Medicare Advantage provider ChenMed

New weight loss drugs vying to be the next Wegovy or Mounjaro

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

Malaria cases in Florida and Texas: Here’s what you need to know

Radiology is caught between AI's potential and concern for patients

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

WATCH: Why do bright lights make us see spots?

As demand for Covid shots wanes, Moderna seeks its next success

Pig kidney works a record two months in donated body

The high cost of giving birth even with insurance

WATCH: Why do bright lights make us see spots?

The cancer drug shortage isn’t new — and neither are the solutions

Food makers to regulators: Ultra

leisure time

Americans' trust in science, scientist continues decline: Report

Pregnancy discrimination could be enabled by AI

Acelyrin, a rare IPO success, stumbles in its first big test

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Regeneron agrees to White House price limits on anti

Acelyrin, a rare IPO success, stumbles in its first big test

focus

hotspot

focus

explore